89bio, Inc. Profile Avatar - Palmy Investing

89bio, Inc.

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibrob…

Biotechnology
US, San Francisco [HQ]

Government Awards Analysis Beta

Obligations Over-Time

Awards
Obligations

89bio, Inc. has no obligation with a government/award agency.

Latest Obligations

Contracts
$ 0.0
IDVs
$ 0.0
Direct Payments
$ 0.0
Grants
$ 0.0
Loans
$ 0.0
Other Payments
$ 0.0
vs. Previous FY
Contracts
$ 0.0
IDVs
$ 0.0
Direct Payments
$ 0.0
Grants
$ 0.0
Loans
$ 0.0
Other Payments
$ 0.0

Spending By Type

Awards
Obligations

89bio, Inc. can't present spending by time.

Get PRO Today

With PRO you will unlock all insights related to government awards of 89bio, Inc..

End of ETNB's Analysis
CIK: 1785173 CUSIP: 282559103 ISIN: US2825591033 LEI: - UEI: -
Secondary Listings
ETNB has no secondary listings inside our databases.